Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 131 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Follow-Up Questions
Prelude Therapeutics Inc의 CEO는 누구입니까?
Dr. Krishna Vaddi은 2016부터 회사에 합류한 Prelude Therapeutics Inc의 Chief Executive Officer입니다.
PRLD 주식의 가격 성능은 어떻습니까?
PRLD의 현재 가격은 $0.9898이며, 전 거래일에 increased 0.5% 하였습니다.
Prelude Therapeutics Inc의 주요 사업 주제나 업종은 무엇입니까?
Prelude Therapeutics Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Prelude Therapeutics Inc의 시가총액은 얼마입니까?
Prelude Therapeutics Inc의 현재 시가총액은 $56.0M입니다
Prelude Therapeutics Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 6명의 분석가가 Prelude Therapeutics Inc에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 5명의 매수, 1명의 보유, 1명의 매도, 그리고 3명의 강력한 매도를 포함합니다
